Novo Nordisk Sues Lilly Over Weight Loss Ads | Business and Finance News

Novo Nordisk is suing Eli Lilly to halt misleading ads comparing their weight loss drugs, arguing that Lilly’s marketing unfairly portrays its products as superior by using lower doses of Novo’s own drugs—when higher-dose versions show nearly identical results. As the $100 billion obesity drug market heats up, this legal showdown pits two giants against each other, with Novo demanding corrective ads and Lilly denying any wrongdoing. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3759b57545bdadec